Stents to cost less, poor will benefit most
The stents used for people suffering from coronary heart diseases are set to get cheaper in India after the Union health ministry accepted the recommendations of a sub-committee looking into the issue.
Asian Age Mumbai News on Jul 23, 2016
The stents used for people suffering from coronary heart diseases are set to get cheaper in India after the Union health ministry accepted the recommendations of a sub-committee looking into the issue.
Asian Age Mumbai News on Jul 23, 2016
Two Day Seminar - Design Controls for Medical Devices - Regulations, Myths, Challenges, and Best Practices (Boston, MA, United States - September 8-9, 2016) - Research and Markets
Areas Covered in the Session:
- Expectations
- Regulations
- Process
- Lessons Learned
- Myths
- Challenges
- Best Practices
- Inspection Readiness
Financial Buzz on Jul 21, 2016
Areas Covered in the Session:
- Expectations
- Regulations
- Process
- Lessons Learned
- Myths
- Challenges
- Best Practices
- Inspection Readiness
Financial Buzz on Jul 21, 2016
STENTYS Enrolls First Patient in Left Main Clinical Trial
STENTYS (Paris:STNT) (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces that it has commenced enrolling patients in the TRUNC trial, which is designed to evaluate the long-term safety and efficacy of the Xposition S stent in the treatment of unprotected left main coronary artery disease.
Financial Buzz on Jul 19, 2016
STENTYS (Paris:STNT) (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces that it has commenced enrolling patients in the TRUNC trial, which is designed to evaluate the long-term safety and efficacy of the Xposition S stent in the treatment of unprotected left main coronary artery disease.
Financial Buzz on Jul 19, 2016
Washington Healthcare Update
This Week: Double Issue — Congress leaves for seven weeks, Congress sends opioid legislation to the President…More co-ops fail…The Supreme Court rules on Texas Abortion Case and Washington state Pharmacists and Religious Freedom Case…Hearings on MACRA, Stark, co-ops, cost-sharing and more.
McGuireWoods Legal Updates on Jul 19, 2016
This Week: Double Issue — Congress leaves for seven weeks, Congress sends opioid legislation to the President…More co-ops fail…The Supreme Court rules on Texas Abortion Case and Washington state Pharmacists and Religious Freedom Case…Hearings on MACRA, Stark, co-ops, cost-sharing and more.
McGuireWoods Legal Updates on Jul 19, 2016
Medical Device Alert - The European Commission published a revised MEDDEV on the classification of stand alone software as medical device
On 15 July 2016, the European Commission issued a revised version of MEDDEV 2.1/6 entitled “Guidelines on the qualification and classification of stand alone software used in healthcare within the regulatory framework of medical devices“. This new document is intended to replace the original version of MEDDEV 2.1/6 which was issued in January 2012. The revisions to the original document introduced by the new MEDDEV 2.1/6 are, however, fairly limited.
Lexology - Company & Commercial, Healthcare & Life Sciences, IT & Data Protection, Intellectual Property and Product Regulation & Liability on Jul 18, 2016
On 15 July 2016, the European Commission issued a revised version of MEDDEV 2.1/6 entitled “Guidelines on the qualification and classification of stand alone software used in healthcare within the regulatory framework of medical devices“. This new document is intended to replace the original version of MEDDEV 2.1/6 which was issued in January 2012. The revisions to the original document introduced by the new MEDDEV 2.1/6 are, however, fairly limited.
Lexology - Company & Commercial, Healthcare & Life Sciences, IT & Data Protection, Intellectual Property and Product Regulation & Liability on Jul 18, 2016
Expert Testimony Excluded as Unqualified in the Field of “Retroactive Mind Reading of Patent Examiners”
The court granted plaintiff's motion to exclude the testimony of defendant's patent expert regarding possible patent examiner responses as unqualified. "[Defendant's expert] provides opinions about two possible patent examiner responses. First, he opines about what an examiner 'could' have done if informed of [a prior art] Abstract. Second, he opines that 'under PTO procedure, by a preponderance of the evidence, the surgeries would have been considered not experimental.'
Justia - Recent Intellectual Property Law Posts on Jul 22, 2016
The court granted plaintiff's motion to exclude the testimony of defendant's patent expert regarding possible patent examiner responses as unqualified. "[Defendant's expert] provides opinions about two possible patent examiner responses. First, he opines about what an examiner 'could' have done if informed of [a prior art] Abstract. Second, he opines that 'under PTO procedure, by a preponderance of the evidence, the surgeries would have been considered not experimental.'
Justia - Recent Intellectual Property Law Posts on Jul 22, 2016
|